Added value of whole ‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel

ConclusionsIn advanced and refractory cancer patients in whom no MBTR was recommended from TGP/aCGH, WES/RNA-Seq allowed to identify more alterations which may in turn, in a limited fraction of patients, lead to new MBTR.

Source: Cancer Medicine - March 30, 2024 Category: Cancer & Oncology Authors: Armelle Dufresne, Val éry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, Séverine Tabone‐Eglinger, Philippe Cassier, Olivier Trédan, Nadège Corradini, Armelle Vinceneux, Aurélie Swalduz, Alain Viari, Sylvie Chabaud, David P Tags: RESEARCH ARTICLE Source Type: research